Pili Protein 65.5 kDa of Klebsiella pneumoniae Induced a Decrease in IL-10 in Mice

Dini Agustina, Mei Liana Wati, Desie Dwi Wisudanti, Muhammad Ali Shodikin, Diana Chusna Mufida, Enny Suswati


Klebsiella pneumoniae is one of the leading cause of nosocomial infection worldwide with clinical isolates mostly found in Multi-Drug Resistant (MDR) or Extensively Drug-Resistant (XDR). This makes therapeutic options due to this bacteria limited. Several studies have shown that the pili protein of K. pneumoniae with different molecular weights plays a role in the virulence factor, as they are hemagglutinin and adhesin proteins. Pili protein 65.5 kDa of K. pneumoniae can be considered as the antigen candidate for vaccines. This study aimed to determine the immune response based on the IL-10 level as induced by pili protein 65.5 kDa K. pneumoniae. This study was conducted from October 2020 to March 2021 at the Faculty of Mathematics and Natural Sciences and Faculty of Medicine of Jember University. This was true experimental with post-test only controlled group design on 27 male BALB/c mice which divided into 3 groups: K1, K2, and K3. The groups were induced with sterile PBS, pili protein and Freund’s adjuvant, and Freund’s adjuvant only, respectively. Samples were drawn through cardiac puncture, then serum was taken to measure the IL-10 levels using the ELISA method. Hemagglutination test showed a positive result with 1/8 as the highest titer. Results showed that the mean IL-10 levels were 290.92±45.33; 235.05±44.53; 218.54±64,81 for K1, K2, and K3, respectively. One-way ANOVA test results showed a statistical difference between groups (p=0,019). This research shows that pili protein 65.5 kDa K. pneumoniae decreases the IL-10 level. However, when it is provided with the Freund’s Adjuvant, there is no proof of the immunogenicity when compared to the control group.


Interleukin-10, immune response, Klebsiella pneumoniae, pili protein

Full Text:



  1. Lenchenko E, Blumenkrants D, Sachivkina N, Shadrova N, Ibragimova A. Morphological and adhesive properties of Klebsiella pneumoniae biofilms. Vet World. 2020;13(1): 197–200.
  2. Opoku-Temeng C, Kobayashi SD, DeLeo FR. Klebsiella pneumoniae capsule polysaccharide as a target for therapeutics and vaccines. Comput Struct Biotechnol J. 2019;17:1360.
  3. Fagundes CT, Amaral FA, Vieira AT, Soares AC, Pinho V, Nicoli JR, et al. Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J Immunol. 2012;188(3):1411–20.
  4. Peñaloza HF, Noguera LP, Riedel CA, Bueno SM. Expanding the current knowledge about the role of interleukin-10 to major concerning bacteria. Front Microbiol. 2018;9:2047.
  5. Agustina D, Sumarno, Noorhamdani. Inhibition of Klebsiella pneumoniae adhesion in mice enterocytes by antibodies of hemagglutinin pili protein with MW 12.8 kDa of Klebsiella pneumoniae. J Trop Life Sci. 2014;4(1):19–25.
  6. Dita RF, Agustina D, Rachmawati DA, Suswati E, Mufida DC. Protein which serves as a virulence factor. J Agromed Med Sci. 2019;5(2):69–76.
  7. Kurniawati LR, Shodikin MA, Agustina D, Sofiana KD. Protein Pili 96,4 KDA klebsiella pneumoniae sebagai protein hemaglutinin dan adhesin. Indones J Heal Sci. 2021;5(1):25.
  8. Levinson W. Review of Microbiology and Immunology. 12th ed. United States: Mc Graw-Hill Companies, Inc; 2012.
  9. CUSABIO. Mouse Interleukin 10 (IL-10) ELISA Kit. Cat Number CSB-E04608m. 17:1–14.
  10. Slieman TA, Leheste J. Introduction to immunological techniques in the clinical laboratory. Methods Microbiol. 2020. 47;1–16.
  11. Nuraningsih, Darmawati S, Santosa B. Aktivitas hemaglutinasi protein pilli salmonella typhi terhadap eritrosit manusia dan domba. Pros Semin Nas Mhs Unimus. 2018;1:86–90.
  12. Fitrianingsih AA. Haemaglutination of shigella flexneri subunit pili protein 18 kda as a molecule adhesion in mice enterocytes. J Islam Pharm. 2017;2(1):22.
  13. Carrillo JLM, Rodríguez FPC, Coronado OG, García MAM, Cordero JFC. Physiology and pathology of innate immune response against pathogens. In: Physiology and Pathology of Immunology. InTech; 2017.
  14. Bengoechea JA, Sa Pessoa J. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019;43(2):123–44.
  15. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, et al. IFN-γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity. 2006;24(5):563–74.
  16. Setiawan H, Nugraha J. Analisis kadar IFN-γ dan IL-10 pada PBMC penderita tuberkulosis aktif, laten dan orang sehat, setelah di stimulasi dengan antigen ESAT-6. J Biosains Pascasarj. 2016;18(1):50.
  17. Duell BL, Tan CK, Carey AJ, Wu F, Cripps AW, Ulett GC. Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol. 2012;64(3):295–313.
  18. Antibody Production (Immunogen Preparation) | Thermo Fisher Scientific - ID.
  19. Yang M, Wang J, Chen C, Ma Y, He S, Wang C. The expression and significance of IL-6 and IL-10 in the process of clinical common bacteria bloodstream infection in the mouse models analyzed by the Luminex® xMAPTM System. Front Lab Med. 2017;1(2):55–8.
  20. Ng THS, Britton GJ, Hill E V., Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129.
  21. Blin A. Vaccine adjuvants. Actual Pharm. 2019;58(584):52–5.
  22. Blanco-Pérez F, Papp G, Goretzki A, Möller T, Anzaghe M, Schülke S. Adjuvant allergen fusion proteins as novel tools for the treatment of type i allergies. Arch Immunol Ther Exp (Warsz). 2019;67(5):273–93.
  23. Apostólico JDS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res. 2016;2016.

DOI: https://doi.org/10.15395/mkb.v54n3.2690

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


This Journal indexed by




Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats